TG Therapeutics’ highly potential pipeline, is poised to fire up the market in the year 2021

• Chronic Lymphocytic Leukemia (CLL)
• Marginal Zone Lymphoma (MZL)
• Follicular Lymphoma (FL)
• Multiple Sclerosis (MS)

In June 2020 the company updated about receiving $240 million in gross proceeds through a public offering and with four of their ongoing programmes in phase III, looking forward to put it here.

Key Triggers

• Potential PDUFA date for umbralisib to treat rel/ref Marginal Zone Lymphoma (MZL) (Feb 15, 2021)
• Potential PDUFA date for umbralisib to treat rel/ref Follicular Lymphoma (FL) (June 15, 2021)

Clinical Results Timeline to WATCH (Data can be presented anytime between 2H 2020 – Q1 2021)

• Reporting topline data from our Phase 3 ULTIMATE program in Multiple Sclerosis.
• Presenting of complete data from the UNITY-NHL FL and MZL single agent umbralisib cohorts
• Presenting from the UNITY-CLL Phase 3 trial, as well as updated data from the triple combination trials, which is believed to set the stage for the future of U2 in CLL and non-Hodgkin’s Lymphoma.

TG therapeutics currently has a very strong pipeline of which 4 of their ongoing programmes in phase III.

The most advanced clinical programmes under TG Therapeutics’ pipeline

Data showing immense potential in TG Therapeutics’ ongoing clinical programmes

As per the latest updates available, TG Therapeutics’ ongoing programmes have shown immense potential in the data provided.

UNITY-CLL Phase III trial [NCT02612311]

The study is evaluating U2 (the combination of umbralisib and ublituximab) in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL). The study met its primary endpoint of PFS (p<.0001), as determined by an Independent Review Committee (IRC).

GENUINE Phase III study [NCT 02301156]

The study evaluating the combination of ublituximab plus ibrutinib compared to ibrutinib alone in patients with relapsed/refractory CLL with high-risk cytogenetics. The results indicated, addition of ublituximab to ibrutinib as compared to ibrutinib alone improved PFS, overall response rate, complete response rate.

UNITY-NHL Phase III study [NCT02793583]

The study is evaluating Umbralisib Monotherapy Cohorts in Relapsed/Refractory MZL & FL. MZL & FL Cohort’s Met Primary End Point of ORR, exceeding 40% ORR hurdle, Interim efficacy analysis of MZL cohort, n=42, showed 52% ORR, including 19% CR.

• On June 15, 2020, the Company announced the completion of the rolling submission of a NDA to the FDA requesting accelerated approval of umbralisib as a treatment for patients with previously treated MZL and FL.
• On August 12, 2020, the Company received notification from the FDA of its acceptance of the Company’s NDA for umbralisib as a treatment for patients with previously treated MZL and FL.

TG Therapeutics’ Market Opportunity

• For Ublituximab Monotherapy in Multiple sclerosis
  • Estimate $1-2 Billion annual market opportunity in the US alone for ublituximab in MS with Global Market Size >$30 Billion by 2025
• For Umbralisib + Ublituximab (U2) and Ublituximab + Ibrutinib- CLL Market Opportunity
  • 115,000 Americans living with CLL
  • 20,000 newly diagnosed patients each year
  • 20,000 previously treated patients seeking treatment each year

What makes TG Therapeutics’ pipeline highly potential and extraordinary?

TG Therapeutics’ Ublituximab (TG-1101) is a next generation glycoengineered monoclonal antibody targeting specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. It has shorter infusion time than other approved anti-CD20s. Umbralisib (TGR-1202) is an oral, once-daily, dual inhibitor of PI3K-delta and CK1-epsilon.

Both ublituximab and umbralisib, or the combination of which is referred to as “U2”, are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis.

Additionally, the Company has recently brought into Phase 1 clinical development products, TG-1501, its anti-PD-L1 monoclonal antibody, TG-1701, its covalently-bound Bruton’s Tyrosine Kinase (BTK) inhibitor and TG-1801, its anti-CD47/CD19 bispecific antibody. 

Michael S. Weiss, TG Therapeutics’ Executive Chairman and Chief Executive Officer, said

“With one completed NDA submission, positive topline data from our UNITY-CLL Phase 3 trial, and a healthy balance sheet with over $275 million in cash, we are well positioned to execute on our remaining milestones for this year as well as transition from a development stage company to a fully-integrated commercial organization”

TG Therapeutics’ Market Strategy

• The company will be using $275.6 millions of their cash, as well as future availabilities under the Company’s debt and ATM facility to fund the Company’s planned operations through the end of 2021.
• TG Therapeutics is well positioned to achieve their remaining milestones for this year and are looking forward for transition from a development stage company to a fully integrated commercial organization.

TG Therapeutics’ Q2 financial report and the updates on the ongoing trials surely puts them at the top. Now the company aims to make its way pass 2020 with some top announcements and to capitalize the early 2021.

Currently, the company is at an advanced stage of clinical development with two experimental therapies targeting hematological malignancies and autoimmune diseases. TG Therapeutics’ ongoing U2 clinical program has the potential to address unmet needs in the CLL, MZL, FL and MS. Their ongoing clinical program has shown high efficacy as TG therapies expect to announce best outcomes by the end of 2020 or early 2021.

Click here for more information on the direct and Indirect competitors for Elacestrant in ER+/HER2- mBC. If you wish to learn more on how Mellalta can be of assistance, Click here.